BR112022016212A2 - Método para detectar tumor ovariano maligno, e, uso de um anticorpo - Google Patents

Método para detectar tumor ovariano maligno, e, uso de um anticorpo

Info

Publication number
BR112022016212A2
BR112022016212A2 BR112022016212A BR112022016212A BR112022016212A2 BR 112022016212 A2 BR112022016212 A2 BR 112022016212A2 BR 112022016212 A BR112022016212 A BR 112022016212A BR 112022016212 A BR112022016212 A BR 112022016212A BR 112022016212 A2 BR112022016212 A2 BR 112022016212A2
Authority
BR
Brazil
Prior art keywords
ovarian tumors
antibody
malignant ovarian
distinct
tfpi2
Prior art date
Application number
BR112022016212A
Other languages
English (en)
Inventor
Miyagi Etsuko
Arakawa Noriaki
Ohtake Norihisa
Myoba Shohei
Original Assignee
Public Univ Corp Yokohama City Univ
Tosoh Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Public Univ Corp Yokohama City Univ, Tosoh Corp filed Critical Public Univ Corp Yokohama City Univ
Publication of BR112022016212A2 publication Critical patent/BR112022016212A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8114—Kunitz type inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

MÉTODO PARA DETECTAR TUMOR OVARIANO MALIGNO, E, USO DE UM ANTICORPO. A presente invenção aborda o problema de prover um método para detectar tumores ovarianos malignos distintamente de tumores ovarianos benignos e um reagente que pode ser usado no método. Este método para detectar tumores ovarianos malignos (excluindo carcinoma seroso de alto grau) distintamente de tumores ovarianos benignos é distinguido pela quantidade de TFPI2 em uma amostra originária de um paciente ser medida. Além disso, um anticorpo que reconhece especificamente o polipeptídeo de processamento de TFPI2 e TFPI2 intacto é incluído em um reagente para detectar tumores ovarianos malignos (excluindo carcinoma seroso de alto grau) distintamente de tumores ovarianos benignos.
BR112022016212A 2020-02-26 2021-02-09 Método para detectar tumor ovariano maligno, e, uso de um anticorpo BR112022016212A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020030210 2020-02-26
PCT/JP2021/004736 WO2021172000A1 (ja) 2020-02-26 2021-02-09 卵巣悪性腫瘍の検出方法及び検出試薬

Publications (1)

Publication Number Publication Date
BR112022016212A2 true BR112022016212A2 (pt) 2022-10-04

Family

ID=77490489

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022016212A BR112022016212A2 (pt) 2020-02-26 2021-02-09 Método para detectar tumor ovariano maligno, e, uso de um anticorpo

Country Status (8)

Country Link
US (1) US20230122642A1 (pt)
EP (1) EP4113119A4 (pt)
JP (1) JPWO2021172000A1 (pt)
CN (1) CN115151821A (pt)
AU (1) AU2021227181A1 (pt)
BR (1) BR112022016212A2 (pt)
CA (1) CA3172404A1 (pt)
WO (1) WO2021172000A1 (pt)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068054A2 (en) * 2002-02-13 2003-08-21 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Services Identification of ovarian cancer tumor markers and therapeutic targets
WO2004108896A2 (en) * 2003-06-03 2004-12-16 The Board Of Trustees Of The University Of Arkansas Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors
ATE557277T1 (de) * 2003-09-24 2012-05-15 Oncotherapy Science Inc Verfahren zur diagnose von endometriose mittels tfpi-2 protein
WO2011102461A1 (ja) 2010-02-22 2011-08-25 公立大学法人横浜市立大学 卵巣明細胞腺癌に特異的に発現しているタンパク質とその応用
JP5906447B2 (ja) * 2011-01-13 2016-04-20 国立研究開発法人産業技術総合研究所 上皮性卵巣癌鑑別マーカー
JP6074676B2 (ja) * 2011-08-19 2017-02-08 公立大学法人横浜市立大学 組織因子経路阻害因子２（ｔｆｐｉ２）測定による卵巣明細胞腺癌の検査方法および検査薬
CN107001437B (zh) * 2014-11-27 2021-10-29 公立大学法人横滨市立大学 卵巢透明细胞腺癌的检查方法及检查药
JP6760562B2 (ja) * 2016-09-30 2020-09-23 公立大学法人横浜市立大学 卵巣明細胞癌患者の予後を予測するための情報提供方法
EP3657170A1 (en) * 2018-11-20 2020-05-27 Philipps-Universität Marburg Method for the early detection and diagnosis of primary and relapsed ovarian carcinoma (oc)

Also Published As

Publication number Publication date
EP4113119A1 (en) 2023-01-04
AU2021227181A1 (en) 2022-09-22
WO2021172000A1 (ja) 2021-09-02
US20230122642A1 (en) 2023-04-20
CA3172404A1 (en) 2021-09-02
CN115151821A (zh) 2022-10-04
JPWO2021172000A1 (pt) 2021-09-02
EP4113119A4 (en) 2024-03-06

Similar Documents

Publication Publication Date Title
Tan et al. Prognostic significance of lymphocyte to monocyte ratio in colorectal cancer: A meta-analysis
Jiang et al. Using an AMACR (P504S)/34βE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens
Mishra et al. Role of B cell development marker CD10 in cancer progression and prognosis
Iseki et al. Impact of the preoperative controlling nutritional status (CONUT) score on the survival after curative surgery for colorectal cancer
McGee et al. Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors
Kristiansen et al. GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics
Sadlecki et al. The Role of Hypoxia‐Inducible Factor‐1α, Glucose Transporter‐1,(GLUT‐1) and Carbon Anhydrase IX in Endometrial Cancer Patients
Lobo et al. High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer
Tsai et al. Reduction of global 5-hydroxymethylcytosine is a poor prognostic factor in breast cancer patients, especially for an ER/PR-negative subtype
Roudi et al. Clinical significance of putative cancer stem cell marker CD44 in different histological subtypes of lung cancer
Barr et al. PAX-8 expression in renal tumours and distant sites: a useful marker of primary and metastatic renal cell carcinoma?
Sato et al. Signal transducer and activator of transcription-3 and breast cancer prognosis
Yang et al. TNFAIP 8 overexpression is associated with lymph node metastasis and poor prognosis in intestinal‐type gastric adenocarcinoma
Xu et al. Prognostic value of Ki-67 in stage I non-small-cell lung cancer: a meta-analysis involving 1931 patients
Senel et al. Prognostic value of cancer stem cell markers CD44 and ALDH1/2 in gastric cancer cases
Ni et al. Short stature homeobox 2 methylation as a potential noninvasive biomarker in bronchial aspirates for lung cancer diagnosis
Alkotyfan et al. Cyfra 21-1 as a Tumor Marker for Follow-up of Patients with Squamous Cell Carcinoma of the Oropharnyx
BR112016007037A2 (pt) método para detectar câncer pancreático, anticorpo monoclonal e kit
RU2012129913A (ru) Способ диагностики злокачественной опухоли
Didem et al. Clinical significance of serum tenascin-c levels in epithelial ovarian cancer
De Nunzio et al. Serum levels of chromogranin A are not predictive of high-grade, poorly differentiated prostate cancer: results from an Italian biopsy cohort
BR112022016212A2 (pt) Método para detectar tumor ovariano maligno, e, uso de um anticorpo
Moore et al. Decreased UCHL1 expression as a cytologic biomarker for aggressive behavior in pancreatic neuroendocrine tumors
Harvey et al. Diagnostic utility of P504S/p63 cocktail, prostate-specific antigen, and prostatic acid phosphatase in verifying prostatic carcinoma involvement in seminal vesicles: a study of 57 cases of radical prostatectomy specimens of pathologic stage pT3b
Cai et al. Correlation of multiple proteins with clinicpathological features and its prognostic significance in colorectal cancer with signet-ring cell component.